MiNK Therapeutics is a precision oncology company that is revolutionizing the field of cell therapy. They are focused on developing allogeneic, invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases. Their lead product is an off-the-shelf, targeted cell therapy based on iNKT cells, which have a dual-mechanism of action and combine the killing features of natural killer (NK) cells with the durable memory response of T cells.

The team at MiNK Therapeutics is dedicated to bringing iNKT cells to the next level by utilizing innovative technology and engineering capabilities. They have demonstrated that these cells can be further engineered or edited for super-targeting, making them highly effective in treating solid tumor cancers. With a focus on precision and personalized medicine, MiNK Therapeutics is at the forefront of cell therapy manufacturing technology to deliver these living medicines at scale.

Their mission is to improve the lives of patients with cancer and other life-threatening diseases through pioneering cell therapies